| 引用本文: | 王晓彤,林海雄,金远林.艾司唑仑治疗失眠症临床疗效及安全性的网状Meta分析[J].中国现代应用药学,2018,35(5):735-740. |
| WANG Xiaotong,LIN Haixiong,JIN Yuanlin.Network Meta-Analysis of Clinical Efficacy and Safety of Estazolam For Insomnia[J].Chin J Mod Appl Pharm(中国现代应用药学),2018,35(5):735-740. |
|
| 摘要: |
| 目的 运用网状meta分析探究艾司唑仑、右佐匹克隆、佐匹克隆、米氮平、米氮平联合艾司唑仑在调节失眠症患者匹兹堡睡眠质量指数（PSQI）、睡眠障碍评定量表（SDRS）、睡眠自评量表（SRSS）、阿森斯失眠量表（AIS）、药物不良反应（TESS）的差异。方法 收集截止至2016年11月CNKI、维普、万方、Pubmed数据库中上述药物在治疗失眠症患者的临床试验资料，文章质量评估用Jadad评分，研究结果的分析用Gemtc 14.3、Stata 13、RevMan 5.3软件。结果 纳入13篇研究，Meta分析发现：与艾司唑仑相比，米氮平联合艾司唑仑的PSQI较低[WMD=-6.67，95% CI （-8.38，-4.96），P<0.000 01]；米氮平联合艾司唑仑的AIS较低[WMD=-3.73，95% CI （-4.51，-2.95），P<0.000 01]；佐匹克隆的SDRS较低[WMD=-2.50，95% CI （-3.71，-1.28），P<0.000 1]。间接网状meta分析显示：SDRS依次为艾司唑仑>右佐匹克隆>佐匹克隆；AIS依次为艾司唑仑>佐匹克隆>米氮平联合艾司唑仑；TESS依次为艾司唑仑>佐匹克隆>右佐匹克隆。结论 艾司唑仑降低失眠患者SDRS、AIS、TESS均不具备明显优势，网状meta分析方法发掘药物疗效与安全性具有一定的参考价值。 |
| 关键词: 艾司唑仑 失眠症 网状meta分析 |
| DOI：10.13748/j.cnki.issn1007-7693.2018.05.024 |
| 分类号:R969.3 |
| 基金项目: |
|
| Network Meta-Analysis of Clinical Efficacy and Safety of Estazolam For Insomnia |
|
WANG Xiaotong1, LIN Haixiong2, JIN Yuanlin1
|
|
1.Shenzhen Bao'an Traditional Chinese Medicine Hospital Group, the Affiliated Hospital of Guangzhou University of Chinese Medicine, Shenzhen 518133, China;2.Guangzhou University of Chinese Medicine, Guangzhou 510405, China
|
| Abstract: |
| OBJECTIVE To evaluate the pittsburg sleep quality index (PSQI), sleep dysfunction rating scale (SDRS), self-rating scale sleep (SRSS), athens insomnia scale (AIS), treatment emergent symptom scale (TESS) of estazolam, eszopiclone, zopiclone, mirtazapine, mirtazapine combine with estazolam for insomnia by using the network meta-analysis.METHODS Clinical trials of the medicine mentioned above for insomnia were identified through 4 databases:CNKI, VIP, Wanfang and PubMed (November 2016 ago). The quality of the included trials were assessed using Jadad scores. Data were analyzed with Gemtc 14.3, Stata 13, Review Manager 5.3 software.RESULTS Thirteen studies were included in the analysis. Compared with estazolam, mirtazapine combine with estazolam had lower PSQI[WMD=-6.67, 95%CI (-8.38, -4.96), P<0.000 01] and AIS[WMD=-3.73, 95%CI (-4.51, -2.95), P<0.000 01], zopiclone had lower SDRS[WMD=-2.50, 95%CI (-3.71, -1.28), P<0.000 1]. Network meta-analysis showed that drugs may be sorted as follows:the sequence of SDRS from high to low were estazolam, eszopiclone, zopiclone; the sequence of AIS from high to low were estazolam, zopiclone, mirtazapine combine with estazolam; the sequence of TESS from high to low were estazolam, zopiclone, eszopiclone.CONCLUSION Estazolam don't show obvious advantages in lower SDRS, AIS, TESS of insomnia. The method of network meta-analysis is efficient in discovering the clinical efficacy and safety of medicine. |
| Key words: estazolam insomnia network meta-analysis |
